Yongmei Yin

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 372 citations

Capecitabine Versus Lapatinib, Breast Oncology, Medicine +8

Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19

Jun Wang, Qian Li, Yongmei Yin et al. · Frontiers in Immunology · 2020 · 277 citations · Full text

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 261 citations

Breast Oncology, Medicine, Pharmacology +8

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Chunmei Bai et al. · The Lancet Oncology · 2020 · 179 citations

Pancreatic Cancer, Medicine, Pathology +5